Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) insider Meir Eini sold 5,000 shares of the stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $6.17, for a total transaction of $30,850.00. Following the completion of the transaction, the insider now directly owns 16,271 shares in the company, valued at $100,392.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Meir Eini also recently made the following trade(s):

  • On Wednesday, January 10th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The stock was sold at an average price of $6.05, for a total transaction of $30,250.00.
  • On Thursday, January 4th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The stock was sold at an average price of $6.68, for a total transaction of $33,400.00.
  • On Tuesday, January 2nd, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The stock was sold at an average price of $6.18, for a total transaction of $30,900.00.

Foamix Pharmaceuticals Ltd (FOMX) traded up $0.01 during trading hours on Friday, reaching $6.41. 58,087 shares of the company were exchanged, compared to its average volume of 92,639. Foamix Pharmaceuticals Ltd has a 1-year low of $4.03 and a 1-year high of $11.11. The company has a market capitalization of $239.57, a price-to-earnings ratio of -3.98 and a beta of 1.62.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative return on equity of 54.81% and a negative net margin of 1,439.32%. The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.90 million. During the same period in the prior year, the business posted ($0.19) earnings per share. Foamix Pharmaceuticals’s revenue was down 64.6% compared to the same quarter last year. analysts anticipate that Foamix Pharmaceuticals Ltd will post -1.35 EPS for the current fiscal year.

A number of equities analysts recently commented on the stock. HC Wainwright set a $12.00 price target on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, January 5th. Guggenheim reaffirmed a “buy” rating and set a $8.00 price target on shares of Foamix Pharmaceuticals in a research report on Thursday, December 14th. Finally, Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th.

Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its position in Foamix Pharmaceuticals by 1,738.5% during the third quarter. Wells Fargo & Company MN now owns 47,801 shares of the specialty pharmaceutical company’s stock worth $265,000 after acquiring an additional 45,201 shares during the period. PDT Partners LLC acquired a new stake in Foamix Pharmaceuticals during the second quarter worth about $304,000. UBS Asset Management Americas Inc. grew its stake in Foamix Pharmaceuticals by 1.6% during the second quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after buying an additional 1,633 shares in the last quarter. DAFNA Capital Management LLC grew its stake in Foamix Pharmaceuticals by 9.2% during the second quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock worth $1,650,000 after buying an additional 30,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Foamix Pharmaceuticals by 38.6% during the second quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 151,849 shares in the last quarter. 57.43% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/01/20/foamix-pharmaceuticals-ltd-fomx-insider-sells-30850-00-in-stock.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.